MindMed’s stock jumps 24% after FDA grants breakthrough designation to LSD therapy for a form of anxiety

Move will speed up development of LSD-based drug as a treatment for generalized anxiety disorder.

Previous post Jobless claims stay at 217,000 in early March. Layoffs still low.
Next post GE’s stock extends weekly rally as GE Aerospace sets $15 billion buyback plan